nodes	percent_of_prediction	percent_of_DWPC	metapath
Meloxicam—CYP3A4—bone cancer	0.262	0.505	CbGaD
Meloxicam—PTGS2—bone cancer	0.257	0.495	CbGaD
Meloxicam—PGD—Methotrexate—bone cancer	0.225	0.608	CbGbCtD
Meloxicam—ABCC4—Methotrexate—bone cancer	0.0621	0.168	CbGbCtD
Meloxicam—PTGS2—Cisplatin—bone cancer	0.0562	0.152	CbGbCtD
Meloxicam—CYP2C9—Cisplatin—bone cancer	0.0191	0.0517	CbGbCtD
Meloxicam—CYP3A4—Doxorubicin—bone cancer	0.00745	0.0201	CbGbCtD
Meloxicam—Lornoxicam—PTGS2—bone cancer	0.00136	0.41	CrCbGaD
Meloxicam—Tenoxicam—PTGS2—bone cancer	0.00121	0.365	CrCbGaD
Meloxicam—ABCC4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000775	0.0741	CbGpPWpGaD
Meloxicam—Piroxicam—PTGS2—bone cancer	0.000747	0.226	CrCbGaD
Meloxicam—ABCC4—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.000453	0.0433	CbGpPWpGaD
Meloxicam—CYP2C8—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000375	0.0359	CbGpPWpGaD
Meloxicam—CYP2C8—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.000358	0.0343	CbGpPWpGaD
Meloxicam—ABCC4—Ectoderm Differentiation—BCOR—bone cancer	0.000325	0.0311	CbGpPWpGaD
Meloxicam—ABCC4—Fluoropyrimidine Activity—DHFR—bone cancer	0.000314	0.0301	CbGpPWpGaD
Meloxicam—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000305	0.0292	CbGpPWpGaD
Meloxicam—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.000292	0.0279	CbGpPWpGaD
Meloxicam—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000201	0.0193	CbGpPWpGaD
Meloxicam—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000189	0.0181	CbGpPWpGaD
Meloxicam—CYP2C8—Xenobiotics—CYP3A4—bone cancer	0.000181	0.0173	CbGpPWpGaD
Meloxicam—PGD—NRF2 pathway—GSTP1—bone cancer	0.000174	0.0167	CbGpPWpGaD
Meloxicam—PGD—NRF2 pathway—TGFBR2—bone cancer	0.000174	0.0167	CbGpPWpGaD
Meloxicam—CYP2C8—Tamoxifen metabolism—CYP3A4—bone cancer	0.000174	0.0166	CbGpPWpGaD
Meloxicam—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL3—bone cancer	0.000165	0.0158	CbGpPWpGaD
Meloxicam—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—bone cancer	0.000165	0.0158	CbGpPWpGaD
Meloxicam—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000165	0.0158	CbGpPWpGaD
Meloxicam—PGD—Carbohydrate metabolism—ENO2—bone cancer	0.000164	0.0157	CbGpPWpGaD
Meloxicam—CYP2C8—Metapathway biotransformation—CYP4V2—bone cancer	0.000161	0.0154	CbGpPWpGaD
Meloxicam—ABCC4—Platelet degranulation—SPARC—bone cancer	0.000158	0.0151	CbGpPWpGaD
Meloxicam—ABCC4—Response to elevated platelet cytosolic Ca2+—SPARC—bone cancer	0.000151	0.0144	CbGpPWpGaD
Meloxicam—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.000147	0.0141	CbGpPWpGaD
Meloxicam—Sinusitis—Epirubicin—bone cancer	0.000146	0.0015	CcSEcCtD
Meloxicam—PTGS2—Signaling mediated by p38-alpha and p38-beta—ATF1—bone cancer	0.000146	0.0139	CbGpPWpGaD
Meloxicam—Agranulocytosis—Epirubicin—bone cancer	0.000145	0.00149	CcSEcCtD
Meloxicam—Drowsiness—Doxorubicin—bone cancer	0.000144	0.00148	CcSEcCtD
Meloxicam—Infestation NOS—Doxorubicin—bone cancer	0.000144	0.00148	CcSEcCtD
Meloxicam—Infestation—Doxorubicin—bone cancer	0.000144	0.00148	CcSEcCtD
Meloxicam—Visual impairment—Methotrexate—bone cancer	0.000144	0.00148	CcSEcCtD
Meloxicam—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000143	0.00147	CcSEcCtD
Meloxicam—Hypersensitivity—Cisplatin—bone cancer	0.000142	0.00146	CcSEcCtD
Meloxicam—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000142	0.0135	CbGpPWpGaD
Meloxicam—Renal failure—Doxorubicin—bone cancer	0.000141	0.00145	CcSEcCtD
Meloxicam—Erythema multiforme—Methotrexate—bone cancer	0.000141	0.00145	CcSEcCtD
Meloxicam—Haemoglobin—Epirubicin—bone cancer	0.00014	0.00144	CcSEcCtD
Meloxicam—Stomatitis—Doxorubicin—bone cancer	0.00014	0.00144	CcSEcCtD
Meloxicam—Jaundice—Doxorubicin—bone cancer	0.00014	0.00144	CcSEcCtD
Meloxicam—Rhinitis—Epirubicin—bone cancer	0.00014	0.00144	CcSEcCtD
Meloxicam—Urinary tract infection—Doxorubicin—bone cancer	0.00014	0.00144	CcSEcCtD
Meloxicam—Conjunctivitis—Doxorubicin—bone cancer	0.00014	0.00144	CcSEcCtD
Meloxicam—Hepatitis—Epirubicin—bone cancer	0.00014	0.00144	CcSEcCtD
Meloxicam—Haemorrhage—Epirubicin—bone cancer	0.00014	0.00144	CcSEcCtD
Meloxicam—Eye disorder—Methotrexate—bone cancer	0.000139	0.00143	CcSEcCtD
Meloxicam—Tinnitus—Methotrexate—bone cancer	0.000139	0.00143	CcSEcCtD
Meloxicam—Asthenia—Cisplatin—bone cancer	0.000139	0.00142	CcSEcCtD
Meloxicam—Pharyngitis—Epirubicin—bone cancer	0.000139	0.00142	CcSEcCtD
Meloxicam—Cardiac disorder—Methotrexate—bone cancer	0.000138	0.00142	CcSEcCtD
Meloxicam—Sweating—Doxorubicin—bone cancer	0.000138	0.00142	CcSEcCtD
Meloxicam—Urinary tract disorder—Epirubicin—bone cancer	0.000138	0.00142	CcSEcCtD
Meloxicam—Oedema peripheral—Epirubicin—bone cancer	0.000137	0.00141	CcSEcCtD
Meloxicam—Haematuria—Doxorubicin—bone cancer	0.000137	0.00141	CcSEcCtD
Meloxicam—Connective tissue disorder—Epirubicin—bone cancer	0.000137	0.00141	CcSEcCtD
Meloxicam—Urethral disorder—Epirubicin—bone cancer	0.000137	0.00141	CcSEcCtD
Meloxicam—Hepatobiliary disease—Doxorubicin—bone cancer	0.000136	0.0014	CcSEcCtD
Meloxicam—Angiopathy—Methotrexate—bone cancer	0.000135	0.00139	CcSEcCtD
Meloxicam—Sinusitis—Doxorubicin—bone cancer	0.000135	0.00139	CcSEcCtD
Meloxicam—Immune system disorder—Methotrexate—bone cancer	0.000135	0.00139	CcSEcCtD
Meloxicam—Visual impairment—Epirubicin—bone cancer	0.000134	0.00138	CcSEcCtD
Meloxicam—Mediastinal disorder—Methotrexate—bone cancer	0.000134	0.00138	CcSEcCtD
Meloxicam—Agranulocytosis—Doxorubicin—bone cancer	0.000134	0.00138	CcSEcCtD
Meloxicam—Diarrhoea—Cisplatin—bone cancer	0.000132	0.00136	CcSEcCtD
Meloxicam—Erythema multiforme—Epirubicin—bone cancer	0.000132	0.00136	CcSEcCtD
Meloxicam—Alopecia—Methotrexate—bone cancer	0.000132	0.00136	CcSEcCtD
Meloxicam—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000131	0.0126	CbGpPWpGaD
Meloxicam—Mental disorder—Methotrexate—bone cancer	0.000131	0.00134	CcSEcCtD
Meloxicam—Eye disorder—Epirubicin—bone cancer	0.00013	0.00134	CcSEcCtD
Meloxicam—Tinnitus—Epirubicin—bone cancer	0.00013	0.00134	CcSEcCtD
Meloxicam—Malnutrition—Methotrexate—bone cancer	0.00013	0.00134	CcSEcCtD
Meloxicam—Erythema—Methotrexate—bone cancer	0.00013	0.00134	CcSEcCtD
Meloxicam—Haemoglobin—Doxorubicin—bone cancer	0.00013	0.00133	CcSEcCtD
Meloxicam—Flushing—Epirubicin—bone cancer	0.00013	0.00133	CcSEcCtD
Meloxicam—Cardiac disorder—Epirubicin—bone cancer	0.00013	0.00133	CcSEcCtD
Meloxicam—Rhinitis—Doxorubicin—bone cancer	0.000129	0.00133	CcSEcCtD
Meloxicam—PTGS1—Overview of nanoparticle effects—PTGS2—bone cancer	0.000129	0.0124	CbGpPWpGaD
Meloxicam—Hepatitis—Doxorubicin—bone cancer	0.000129	0.00133	CcSEcCtD
Meloxicam—Haemorrhage—Doxorubicin—bone cancer	0.000129	0.00133	CcSEcCtD
Meloxicam—Pharyngitis—Doxorubicin—bone cancer	0.000128	0.00132	CcSEcCtD
Meloxicam—Urinary tract disorder—Doxorubicin—bone cancer	0.000128	0.00131	CcSEcCtD
Meloxicam—Oedema peripheral—Doxorubicin—bone cancer	0.000127	0.00131	CcSEcCtD
Meloxicam—Dysgeusia—Methotrexate—bone cancer	0.000127	0.00131	CcSEcCtD
Meloxicam—Connective tissue disorder—Doxorubicin—bone cancer	0.000127	0.0013	CcSEcCtD
Meloxicam—Angiopathy—Epirubicin—bone cancer	0.000127	0.0013	CcSEcCtD
Meloxicam—Urethral disorder—Doxorubicin—bone cancer	0.000127	0.0013	CcSEcCtD
Meloxicam—Immune system disorder—Epirubicin—bone cancer	0.000126	0.0013	CcSEcCtD
Meloxicam—Mediastinal disorder—Epirubicin—bone cancer	0.000126	0.00129	CcSEcCtD
Meloxicam—Back pain—Methotrexate—bone cancer	0.000126	0.00129	CcSEcCtD
Meloxicam—Arrhythmia—Epirubicin—bone cancer	0.000125	0.00128	CcSEcCtD
Meloxicam—Visual impairment—Doxorubicin—bone cancer	0.000124	0.00128	CcSEcCtD
Meloxicam—Alopecia—Epirubicin—bone cancer	0.000123	0.00127	CcSEcCtD
Meloxicam—Vomiting—Cisplatin—bone cancer	0.000123	0.00126	CcSEcCtD
Meloxicam—Vision blurred—Methotrexate—bone cancer	0.000122	0.00126	CcSEcCtD
Meloxicam—Mental disorder—Epirubicin—bone cancer	0.000122	0.00126	CcSEcCtD
Meloxicam—Erythema multiforme—Doxorubicin—bone cancer	0.000122	0.00126	CcSEcCtD
Meloxicam—Rash—Cisplatin—bone cancer	0.000122	0.00125	CcSEcCtD
Meloxicam—Dermatitis—Cisplatin—bone cancer	0.000122	0.00125	CcSEcCtD
Meloxicam—Malnutrition—Epirubicin—bone cancer	0.000121	0.00125	CcSEcCtD
Meloxicam—Erythema—Epirubicin—bone cancer	0.000121	0.00125	CcSEcCtD
Meloxicam—Eye disorder—Doxorubicin—bone cancer	0.000121	0.00124	CcSEcCtD
Meloxicam—Ill-defined disorder—Methotrexate—bone cancer	0.00012	0.00124	CcSEcCtD
Meloxicam—Tinnitus—Doxorubicin—bone cancer	0.00012	0.00124	CcSEcCtD
Meloxicam—Anaemia—Methotrexate—bone cancer	0.00012	0.00123	CcSEcCtD
Meloxicam—Flushing—Doxorubicin—bone cancer	0.00012	0.00123	CcSEcCtD
Meloxicam—Cardiac disorder—Doxorubicin—bone cancer	0.00012	0.00123	CcSEcCtD
Meloxicam—Flatulence—Epirubicin—bone cancer	0.00012	0.00123	CcSEcCtD
Meloxicam—Tension—Epirubicin—bone cancer	0.000119	0.00123	CcSEcCtD
Meloxicam—Dysgeusia—Epirubicin—bone cancer	0.000119	0.00122	CcSEcCtD
Meloxicam—Nervousness—Epirubicin—bone cancer	0.000118	0.00121	CcSEcCtD
Meloxicam—Back pain—Epirubicin—bone cancer	0.000118	0.00121	CcSEcCtD
Meloxicam—Angiopathy—Doxorubicin—bone cancer	0.000117	0.0012	CcSEcCtD
Meloxicam—Malaise—Methotrexate—bone cancer	0.000117	0.0012	CcSEcCtD
Meloxicam—Muscle spasms—Epirubicin—bone cancer	0.000117	0.0012	CcSEcCtD
Meloxicam—Immune system disorder—Doxorubicin—bone cancer	0.000117	0.0012	CcSEcCtD
Meloxicam—Vertigo—Methotrexate—bone cancer	0.000117	0.0012	CcSEcCtD
Meloxicam—Mediastinal disorder—Doxorubicin—bone cancer	0.000116	0.0012	CcSEcCtD
Meloxicam—Leukopenia—Methotrexate—bone cancer	0.000116	0.0012	CcSEcCtD
Meloxicam—Arrhythmia—Doxorubicin—bone cancer	0.000115	0.00119	CcSEcCtD
Meloxicam—Nausea—Cisplatin—bone cancer	0.000115	0.00118	CcSEcCtD
Meloxicam—Vision blurred—Epirubicin—bone cancer	0.000114	0.00118	CcSEcCtD
Meloxicam—Alopecia—Doxorubicin—bone cancer	0.000114	0.00117	CcSEcCtD
Meloxicam—Cough—Methotrexate—bone cancer	0.000113	0.00116	CcSEcCtD
Meloxicam—Mental disorder—Doxorubicin—bone cancer	0.000113	0.00116	CcSEcCtD
Meloxicam—Ill-defined disorder—Epirubicin—bone cancer	0.000113	0.00116	CcSEcCtD
Meloxicam—Convulsion—Methotrexate—bone cancer	0.000112	0.00116	CcSEcCtD
Meloxicam—Malnutrition—Doxorubicin—bone cancer	0.000112	0.00116	CcSEcCtD
Meloxicam—Erythema—Doxorubicin—bone cancer	0.000112	0.00116	CcSEcCtD
Meloxicam—Anaemia—Epirubicin—bone cancer	0.000112	0.00115	CcSEcCtD
Meloxicam—Flatulence—Doxorubicin—bone cancer	0.000111	0.00114	CcSEcCtD
Meloxicam—Arthralgia—Methotrexate—bone cancer	0.000111	0.00114	CcSEcCtD
Meloxicam—Myalgia—Methotrexate—bone cancer	0.000111	0.00114	CcSEcCtD
Meloxicam—Tension—Doxorubicin—bone cancer	0.00011	0.00113	CcSEcCtD
Meloxicam—Dysgeusia—Doxorubicin—bone cancer	0.00011	0.00113	CcSEcCtD
Meloxicam—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.00011	0.00113	CcSEcCtD
Meloxicam—Malaise—Epirubicin—bone cancer	0.00011	0.00113	CcSEcCtD
Meloxicam—Discomfort—Methotrexate—bone cancer	0.000109	0.00112	CcSEcCtD
Meloxicam—Nervousness—Doxorubicin—bone cancer	0.000109	0.00112	CcSEcCtD
Meloxicam—Vertigo—Epirubicin—bone cancer	0.000109	0.00112	CcSEcCtD
Meloxicam—Syncope—Epirubicin—bone cancer	0.000109	0.00112	CcSEcCtD
Meloxicam—Leukopenia—Epirubicin—bone cancer	0.000109	0.00112	CcSEcCtD
Meloxicam—Back pain—Doxorubicin—bone cancer	0.000109	0.00112	CcSEcCtD
Meloxicam—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000109	0.0104	CbGpPWpGaD
Meloxicam—Muscle spasms—Doxorubicin—bone cancer	0.000108	0.00111	CcSEcCtD
Meloxicam—Palpitations—Epirubicin—bone cancer	0.000107	0.0011	CcSEcCtD
Meloxicam—PTGS1—Eicosanoid Synthesis—PTGS2—bone cancer	0.000107	0.0103	CbGpPWpGaD
Meloxicam—PGD—Metabolism—NDUFA12—bone cancer	0.000107	0.0102	CbGpPWpGaD
Meloxicam—Confusional state—Methotrexate—bone cancer	0.000107	0.0011	CcSEcCtD
Meloxicam—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL3—bone cancer	0.000107	0.0102	CbGpPWpGaD
Meloxicam—Loss of consciousness—Epirubicin—bone cancer	0.000107	0.0011	CcSEcCtD
Meloxicam—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—bone cancer	0.000106	0.0102	CbGpPWpGaD
Meloxicam—Cough—Epirubicin—bone cancer	0.000106	0.00109	CcSEcCtD
Meloxicam—Anaphylactic shock—Methotrexate—bone cancer	0.000106	0.00109	CcSEcCtD
Meloxicam—Vision blurred—Doxorubicin—bone cancer	0.000106	0.00109	CcSEcCtD
Meloxicam—Convulsion—Epirubicin—bone cancer	0.000105	0.00108	CcSEcCtD
Meloxicam—Infection—Methotrexate—bone cancer	0.000105	0.00108	CcSEcCtD
Meloxicam—Hypertension—Epirubicin—bone cancer	0.000105	0.00108	CcSEcCtD
Meloxicam—Ill-defined disorder—Doxorubicin—bone cancer	0.000104	0.00107	CcSEcCtD
Meloxicam—Nervous system disorder—Methotrexate—bone cancer	0.000104	0.00107	CcSEcCtD
Meloxicam—Anaemia—Doxorubicin—bone cancer	0.000104	0.00107	CcSEcCtD
Meloxicam—Thrombocytopenia—Methotrexate—bone cancer	0.000104	0.00107	CcSEcCtD
Meloxicam—Arthralgia—Epirubicin—bone cancer	0.000103	0.00106	CcSEcCtD
Meloxicam—Myalgia—Epirubicin—bone cancer	0.000103	0.00106	CcSEcCtD
Meloxicam—Anxiety—Epirubicin—bone cancer	0.000103	0.00106	CcSEcCtD
Meloxicam—Skin disorder—Methotrexate—bone cancer	0.000103	0.00106	CcSEcCtD
Meloxicam—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000103	0.00106	CcSEcCtD
Meloxicam—Hyperhidrosis—Methotrexate—bone cancer	0.000102	0.00105	CcSEcCtD
Meloxicam—Discomfort—Epirubicin—bone cancer	0.000102	0.00105	CcSEcCtD
Meloxicam—Malaise—Doxorubicin—bone cancer	0.000101	0.00104	CcSEcCtD
Meloxicam—Dry mouth—Epirubicin—bone cancer	0.000101	0.00104	CcSEcCtD
Meloxicam—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000101	0.00967	CbGpPWpGaD
Meloxicam—Vertigo—Doxorubicin—bone cancer	0.000101	0.00104	CcSEcCtD
Meloxicam—Syncope—Doxorubicin—bone cancer	0.000101	0.00104	CcSEcCtD
Meloxicam—Leukopenia—Doxorubicin—bone cancer	0.000101	0.00103	CcSEcCtD
Meloxicam—Confusional state—Epirubicin—bone cancer	0.0001	0.00103	CcSEcCtD
Meloxicam—Palpitations—Doxorubicin—bone cancer	9.93e-05	0.00102	CcSEcCtD
Meloxicam—Anaphylactic shock—Epirubicin—bone cancer	9.92e-05	0.00102	CcSEcCtD
Meloxicam—Oedema—Epirubicin—bone cancer	9.92e-05	0.00102	CcSEcCtD
Meloxicam—Hypotension—Methotrexate—bone cancer	9.9e-05	0.00102	CcSEcCtD
Meloxicam—Loss of consciousness—Doxorubicin—bone cancer	9.88e-05	0.00102	CcSEcCtD
Meloxicam—Infection—Epirubicin—bone cancer	9.85e-05	0.00101	CcSEcCtD
Meloxicam—Cough—Doxorubicin—bone cancer	9.81e-05	0.00101	CcSEcCtD
Meloxicam—Shock—Epirubicin—bone cancer	9.76e-05	0.001	CcSEcCtD
Meloxicam—Convulsion—Doxorubicin—bone cancer	9.74e-05	0.001	CcSEcCtD
Meloxicam—Nervous system disorder—Epirubicin—bone cancer	9.72e-05	0.001	CcSEcCtD
Meloxicam—Thrombocytopenia—Epirubicin—bone cancer	9.71e-05	0.000998	CcSEcCtD
Meloxicam—Hypertension—Doxorubicin—bone cancer	9.71e-05	0.000998	CcSEcCtD
Meloxicam—Tachycardia—Epirubicin—bone cancer	9.68e-05	0.000995	CcSEcCtD
Meloxicam—Musculoskeletal discomfort—Methotrexate—bone cancer	9.65e-05	0.000993	CcSEcCtD
Meloxicam—Skin disorder—Epirubicin—bone cancer	9.63e-05	0.00099	CcSEcCtD
Meloxicam—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	9.63e-05	0.00922	CbGpPWpGaD
Meloxicam—Hyperhidrosis—Epirubicin—bone cancer	9.59e-05	0.000986	CcSEcCtD
Meloxicam—Insomnia—Methotrexate—bone cancer	9.58e-05	0.000985	CcSEcCtD
Meloxicam—Arthralgia—Doxorubicin—bone cancer	9.57e-05	0.000984	CcSEcCtD
Meloxicam—Myalgia—Doxorubicin—bone cancer	9.57e-05	0.000984	CcSEcCtD
Meloxicam—Anxiety—Doxorubicin—bone cancer	9.54e-05	0.000981	CcSEcCtD
Meloxicam—Paraesthesia—Methotrexate—bone cancer	9.51e-05	0.000978	CcSEcCtD
Meloxicam—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	9.5e-05	0.000977	CcSEcCtD
Meloxicam—Discomfort—Doxorubicin—bone cancer	9.46e-05	0.000972	CcSEcCtD
Meloxicam—Dyspnoea—Methotrexate—bone cancer	9.45e-05	0.000971	CcSEcCtD
Meloxicam—PTGS1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	9.43e-05	0.00902	CbGpPWpGaD
Meloxicam—Somnolence—Methotrexate—bone cancer	9.42e-05	0.000969	CcSEcCtD
Meloxicam—Dry mouth—Doxorubicin—bone cancer	9.36e-05	0.000963	CcSEcCtD
Meloxicam—Dyspepsia—Methotrexate—bone cancer	9.33e-05	0.000959	CcSEcCtD
Meloxicam—Hypotension—Epirubicin—bone cancer	9.27e-05	0.000953	CcSEcCtD
Meloxicam—Confusional state—Doxorubicin—bone cancer	9.25e-05	0.000951	CcSEcCtD
Meloxicam—Decreased appetite—Methotrexate—bone cancer	9.21e-05	0.000947	CcSEcCtD
Meloxicam—Anaphylactic shock—Doxorubicin—bone cancer	9.17e-05	0.000943	CcSEcCtD
Meloxicam—Oedema—Doxorubicin—bone cancer	9.17e-05	0.000943	CcSEcCtD
Meloxicam—Gastrointestinal disorder—Methotrexate—bone cancer	9.15e-05	0.000941	CcSEcCtD
Meloxicam—Fatigue—Methotrexate—bone cancer	9.13e-05	0.000939	CcSEcCtD
Meloxicam—Infection—Doxorubicin—bone cancer	9.11e-05	0.000937	CcSEcCtD
Meloxicam—Pain—Methotrexate—bone cancer	9.06e-05	0.000932	CcSEcCtD
Meloxicam—Musculoskeletal discomfort—Epirubicin—bone cancer	9.03e-05	0.000929	CcSEcCtD
Meloxicam—Shock—Doxorubicin—bone cancer	9.03e-05	0.000928	CcSEcCtD
Meloxicam—Nervous system disorder—Doxorubicin—bone cancer	9e-05	0.000925	CcSEcCtD
Meloxicam—Thrombocytopenia—Doxorubicin—bone cancer	8.98e-05	0.000924	CcSEcCtD
Meloxicam—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—bone cancer	8.97e-05	0.00859	CbGpPWpGaD
Meloxicam—Insomnia—Epirubicin—bone cancer	8.97e-05	0.000922	CcSEcCtD
Meloxicam—Tachycardia—Doxorubicin—bone cancer	8.95e-05	0.000921	CcSEcCtD
Meloxicam—Skin disorder—Doxorubicin—bone cancer	8.91e-05	0.000916	CcSEcCtD
Meloxicam—Paraesthesia—Epirubicin—bone cancer	8.9e-05	0.000916	CcSEcCtD
Meloxicam—Hyperhidrosis—Doxorubicin—bone cancer	8.87e-05	0.000912	CcSEcCtD
Meloxicam—PGD—Metabolism—NT5C3A—bone cancer	8.87e-05	0.00849	CbGpPWpGaD
Meloxicam—Dyspnoea—Epirubicin—bone cancer	8.84e-05	0.000909	CcSEcCtD
Meloxicam—Somnolence—Epirubicin—bone cancer	8.81e-05	0.000906	CcSEcCtD
Meloxicam—Feeling abnormal—Methotrexate—bone cancer	8.73e-05	0.000898	CcSEcCtD
Meloxicam—Dyspepsia—Epirubicin—bone cancer	8.73e-05	0.000898	CcSEcCtD
Meloxicam—Gastrointestinal pain—Methotrexate—bone cancer	8.66e-05	0.000891	CcSEcCtD
Meloxicam—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	8.66e-05	0.00829	CbGpPWpGaD
Meloxicam—Decreased appetite—Epirubicin—bone cancer	8.62e-05	0.000886	CcSEcCtD
Meloxicam—Hypotension—Doxorubicin—bone cancer	8.57e-05	0.000882	CcSEcCtD
Meloxicam—Gastrointestinal disorder—Epirubicin—bone cancer	8.56e-05	0.00088	CcSEcCtD
Meloxicam—Fatigue—Epirubicin—bone cancer	8.55e-05	0.000879	CcSEcCtD
Meloxicam—Constipation—Epirubicin—bone cancer	8.48e-05	0.000872	CcSEcCtD
Meloxicam—Pain—Epirubicin—bone cancer	8.48e-05	0.000872	CcSEcCtD
Meloxicam—Urticaria—Methotrexate—bone cancer	8.42e-05	0.000866	CcSEcCtD
Meloxicam—Body temperature increased—Methotrexate—bone cancer	8.38e-05	0.000861	CcSEcCtD
Meloxicam—Abdominal pain—Methotrexate—bone cancer	8.38e-05	0.000861	CcSEcCtD
Meloxicam—Musculoskeletal discomfort—Doxorubicin—bone cancer	8.36e-05	0.00086	CcSEcCtD
Meloxicam—Insomnia—Doxorubicin—bone cancer	8.3e-05	0.000853	CcSEcCtD
Meloxicam—Paraesthesia—Doxorubicin—bone cancer	8.24e-05	0.000847	CcSEcCtD
Meloxicam—Dyspnoea—Doxorubicin—bone cancer	8.18e-05	0.000841	CcSEcCtD
Meloxicam—Feeling abnormal—Epirubicin—bone cancer	8.17e-05	0.00084	CcSEcCtD
Meloxicam—Somnolence—Doxorubicin—bone cancer	8.16e-05	0.000839	CcSEcCtD
Meloxicam—Gastrointestinal pain—Epirubicin—bone cancer	8.11e-05	0.000834	CcSEcCtD
Meloxicam—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—DHFR—bone cancer	8.09e-05	0.00775	CbGpPWpGaD
Meloxicam—Dyspepsia—Doxorubicin—bone cancer	8.08e-05	0.00083	CcSEcCtD
Meloxicam—Decreased appetite—Doxorubicin—bone cancer	7.98e-05	0.00082	CcSEcCtD
Meloxicam—Gastrointestinal disorder—Doxorubicin—bone cancer	7.92e-05	0.000815	CcSEcCtD
Meloxicam—Fatigue—Doxorubicin—bone cancer	7.91e-05	0.000813	CcSEcCtD
Meloxicam—Urticaria—Epirubicin—bone cancer	7.88e-05	0.00081	CcSEcCtD
Meloxicam—Pain—Doxorubicin—bone cancer	7.85e-05	0.000807	CcSEcCtD
Meloxicam—Constipation—Doxorubicin—bone cancer	7.85e-05	0.000807	CcSEcCtD
Meloxicam—Body temperature increased—Epirubicin—bone cancer	7.84e-05	0.000806	CcSEcCtD
Meloxicam—Abdominal pain—Epirubicin—bone cancer	7.84e-05	0.000806	CcSEcCtD
Meloxicam—Hypersensitivity—Methotrexate—bone cancer	7.81e-05	0.000803	CcSEcCtD
Meloxicam—Asthenia—Methotrexate—bone cancer	7.6e-05	0.000782	CcSEcCtD
Meloxicam—Feeling abnormal—Doxorubicin—bone cancer	7.56e-05	0.000777	CcSEcCtD
Meloxicam—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	7.51e-05	0.00719	CbGpPWpGaD
Meloxicam—Gastrointestinal pain—Doxorubicin—bone cancer	7.5e-05	0.000771	CcSEcCtD
Meloxicam—Pruritus—Methotrexate—bone cancer	7.5e-05	0.000771	CcSEcCtD
Meloxicam—CYP2C8—Oxidation by Cytochrome P450—CYP3A4—bone cancer	7.41e-05	0.00709	CbGpPWpGaD
Meloxicam—Hypersensitivity—Epirubicin—bone cancer	7.31e-05	0.000751	CcSEcCtD
Meloxicam—Urticaria—Doxorubicin—bone cancer	7.29e-05	0.00075	CcSEcCtD
Meloxicam—Abdominal pain—Doxorubicin—bone cancer	7.25e-05	0.000746	CcSEcCtD
Meloxicam—Body temperature increased—Doxorubicin—bone cancer	7.25e-05	0.000746	CcSEcCtD
Meloxicam—Diarrhoea—Methotrexate—bone cancer	7.25e-05	0.000746	CcSEcCtD
Meloxicam—Asthenia—Epirubicin—bone cancer	7.11e-05	0.000732	CcSEcCtD
Meloxicam—ABCC4—Fluoropyrimidine Activity—TP53—bone cancer	7.02e-05	0.00672	CbGpPWpGaD
Meloxicam—Pruritus—Epirubicin—bone cancer	7.02e-05	0.000721	CcSEcCtD
Meloxicam—ABCC4—Platelet activation, signaling and aggregation—SPARC—bone cancer	7.01e-05	0.00671	CbGpPWpGaD
Meloxicam—Dizziness—Methotrexate—bone cancer	7.01e-05	0.000721	CcSEcCtD
Meloxicam—ABCC4—NRF2 pathway—TGFBR2—bone cancer	6.93e-05	0.00663	CbGpPWpGaD
Meloxicam—ABCC4—NRF2 pathway—GSTP1—bone cancer	6.93e-05	0.00663	CbGpPWpGaD
Meloxicam—Diarrhoea—Epirubicin—bone cancer	6.78e-05	0.000698	CcSEcCtD
Meloxicam—Hypersensitivity—Doxorubicin—bone cancer	6.76e-05	0.000695	CcSEcCtD
Meloxicam—Vomiting—Methotrexate—bone cancer	6.74e-05	0.000693	CcSEcCtD
Meloxicam—Rash—Methotrexate—bone cancer	6.68e-05	0.000687	CcSEcCtD
Meloxicam—Dermatitis—Methotrexate—bone cancer	6.67e-05	0.000686	CcSEcCtD
Meloxicam—Headache—Methotrexate—bone cancer	6.64e-05	0.000683	CcSEcCtD
Meloxicam—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CDK4—bone cancer	6.62e-05	0.00634	CbGpPWpGaD
Meloxicam—PTGS2—Calcium signaling in the CD4+ TCR pathway—JUN—bone cancer	6.6e-05	0.00631	CbGpPWpGaD
Meloxicam—Asthenia—Doxorubicin—bone cancer	6.58e-05	0.000677	CcSEcCtD
Meloxicam—Dizziness—Epirubicin—bone cancer	6.56e-05	0.000674	CcSEcCtD
Meloxicam—Pruritus—Doxorubicin—bone cancer	6.49e-05	0.000668	CcSEcCtD
Meloxicam—ABCC4—Platelet activation, signaling and aggregation—GNA11—bone cancer	6.41e-05	0.00614	CbGpPWpGaD
Meloxicam—Vomiting—Epirubicin—bone cancer	6.3e-05	0.000648	CcSEcCtD
Meloxicam—Nausea—Methotrexate—bone cancer	6.29e-05	0.000647	CcSEcCtD
Meloxicam—Diarrhoea—Doxorubicin—bone cancer	6.28e-05	0.000646	CcSEcCtD
Meloxicam—Rash—Epirubicin—bone cancer	6.25e-05	0.000643	CcSEcCtD
Meloxicam—Dermatitis—Epirubicin—bone cancer	6.25e-05	0.000642	CcSEcCtD
Meloxicam—Headache—Epirubicin—bone cancer	6.21e-05	0.000639	CcSEcCtD
Meloxicam—PTGS2—Aryl Hydrocarbon Receptor—RB1—bone cancer	6.15e-05	0.00589	CbGpPWpGaD
Meloxicam—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	6.11e-05	0.00585	CbGpPWpGaD
Meloxicam—CYP2C8—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	6.09e-05	0.00583	CbGpPWpGaD
Meloxicam—Dizziness—Doxorubicin—bone cancer	6.07e-05	0.000624	CcSEcCtD
Meloxicam—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	6.03e-05	0.00577	CbGpPWpGaD
Meloxicam—PTGS1—Arachidonic acid metabolism—PTGS2—bone cancer	5.96e-05	0.00571	CbGpPWpGaD
Meloxicam—Nausea—Epirubicin—bone cancer	5.89e-05	0.000606	CcSEcCtD
Meloxicam—Vomiting—Doxorubicin—bone cancer	5.83e-05	0.0006	CcSEcCtD
Meloxicam—ABCC4—Platelet activation, signaling and aggregation—IL3—bone cancer	5.82e-05	0.00557	CbGpPWpGaD
Meloxicam—Rash—Doxorubicin—bone cancer	5.78e-05	0.000595	CcSEcCtD
Meloxicam—Dermatitis—Doxorubicin—bone cancer	5.78e-05	0.000594	CcSEcCtD
Meloxicam—Headache—Doxorubicin—bone cancer	5.75e-05	0.000591	CcSEcCtD
Meloxicam—PTGS2—Signaling mediated by p38-alpha and p38-beta—JUN—bone cancer	5.68e-05	0.00543	CbGpPWpGaD
Meloxicam—Nausea—Doxorubicin—bone cancer	5.45e-05	0.00056	CcSEcCtD
Meloxicam—ABCC4—Transmembrane transport of small molecules—TUBB4B—bone cancer	5.45e-05	0.00521	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	5.18e-05	0.00496	CbGpPWpGaD
Meloxicam—PTGS1—Biological oxidations—CYP3A4—bone cancer	5.01e-05	0.00479	CbGpPWpGaD
Meloxicam—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	4.96e-05	0.00474	CbGpPWpGaD
Meloxicam—ABCC4—Transmembrane transport of small molecules—TUBB2A—bone cancer	4.7e-05	0.0045	CbGpPWpGaD
Meloxicam—PGD—Disease—ENO2—bone cancer	4.64e-05	0.00444	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	4.41e-05	0.00422	CbGpPWpGaD
Meloxicam—PGD—Disease—DHFR—bone cancer	4.3e-05	0.00412	CbGpPWpGaD
Meloxicam—PTGS1—Biological oxidations—GSTP1—bone cancer	4.28e-05	0.0041	CbGpPWpGaD
Meloxicam—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—bone cancer	4.27e-05	0.00408	CbGpPWpGaD
Meloxicam—PTGS2—C-MYB transcription factor network—KIT—bone cancer	4.12e-05	0.00394	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	4.01e-05	0.00384	CbGpPWpGaD
Meloxicam—PGD—Metabolism—ENO2—bone cancer	3.88e-05	0.00372	CbGpPWpGaD
Meloxicam—CYP2C8—Arachidonic acid metabolism—PTGS2—bone cancer	3.85e-05	0.00369	CbGpPWpGaD
Meloxicam—PTGS1—Selenium Micronutrient Network—PTGS2—bone cancer	3.79e-05	0.00363	CbGpPWpGaD
Meloxicam—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—bone cancer	3.75e-05	0.00359	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	3.66e-05	0.0035	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—SPARC—bone cancer	3.61e-05	0.00346	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	3.61e-05	0.00345	CbGpPWpGaD
Meloxicam—PGD—Metabolism—DHFR—bone cancer	3.6e-05	0.00345	CbGpPWpGaD
Meloxicam—PTGS2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	3.59e-05	0.00343	CbGpPWpGaD
Meloxicam—PGD—Metabolism—GNA11—bone cancer	3.37e-05	0.00322	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—CDK4—bone cancer	3.33e-05	0.00319	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—GNA11—bone cancer	3.31e-05	0.00316	CbGpPWpGaD
Meloxicam—CYP2C8—Biological oxidations—CYP3A4—bone cancer	3.23e-05	0.0031	CbGpPWpGaD
Meloxicam—CYP2C8—Metapathway biotransformation—CYP3A4—bone cancer	3.19e-05	0.00305	CbGpPWpGaD
Meloxicam—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	3.13e-05	0.003	CbGpPWpGaD
Meloxicam—PGD—Disease—TGFBR2—bone cancer	3.12e-05	0.00298	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	3.06e-05	0.00292	CbGpPWpGaD
Meloxicam—PGD—Metabolism—CYP3A4—bone cancer	3.05e-05	0.00292	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—NDUFA12—bone cancer	3e-05	0.00287	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—IL3—bone cancer	3e-05	0.00287	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—RB1—bone cancer	2.9e-05	0.00277	CbGpPWpGaD
Meloxicam—CYP2C8—Biological oxidations—GSTP1—bone cancer	2.77e-05	0.00265	CbGpPWpGaD
Meloxicam—CYP2C8—Metapathway biotransformation—GSTP1—bone cancer	2.73e-05	0.00261	CbGpPWpGaD
Meloxicam—CYP2C9—Biological oxidations—CYP3A4—bone cancer	2.63e-05	0.00252	CbGpPWpGaD
Meloxicam—PGD—Metabolism—GSTP1—bone cancer	2.61e-05	0.0025	CbGpPWpGaD
Meloxicam—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	2.6e-05	0.00248	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—NT5C3A—bone cancer	2.49e-05	0.00238	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—NDUFA12—bone cancer	2.38e-05	0.00228	CbGpPWpGaD
Meloxicam—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	2.29e-05	0.00219	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	2.27e-05	0.00217	CbGpPWpGaD
Meloxicam—CYP2C9—Biological oxidations—GSTP1—bone cancer	2.25e-05	0.00215	CbGpPWpGaD
Meloxicam—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	2.22e-05	0.00213	CbGpPWpGaD
Meloxicam—PGD—Disease—KIT—bone cancer	2.13e-05	0.00204	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—MMP9—bone cancer	2.09e-05	0.002	CbGpPWpGaD
Meloxicam—PGD—Disease—BRAF—bone cancer	2e-05	0.00191	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—NT5C3A—bone cancer	1.97e-05	0.00189	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—PLAU—bone cancer	1.97e-05	0.00188	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—NDUFA12—bone cancer	1.94e-05	0.00186	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—EGFR—bone cancer	1.69e-05	0.00162	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	1.68e-05	0.00161	CbGpPWpGaD
Meloxicam—PGD—Disease—MDM2—bone cancer	1.68e-05	0.0016	CbGpPWpGaD
Meloxicam—PGD—Disease—PTGS2—bone cancer	1.62e-05	0.00155	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—NT5C3A—bone cancer	1.61e-05	0.00154	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—NDUFA12—bone cancer	1.58e-05	0.00151	CbGpPWpGaD
Meloxicam—CYP3A4—Biological oxidations—GSTP1—bone cancer	1.48e-05	0.00142	CbGpPWpGaD
Meloxicam—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	1.46e-05	0.0014	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	1.46e-05	0.0014	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—TP53—bone cancer	1.42e-05	0.00136	CbGpPWpGaD
Meloxicam—PGD—Metabolism—PTGS2—bone cancer	1.35e-05	0.00129	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—NT5C3A—bone cancer	1.31e-05	0.00125	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	1.15e-05	0.0011	CbGpPWpGaD
Meloxicam—PGD—Disease—EGFR—bone cancer	1.14e-05	0.0011	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—ENO2—bone cancer	1.09e-05	0.00104	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—NDUFA12—bone cancer	1.04e-05	0.000996	CbGpPWpGaD
Meloxicam—PTGS2—Disease—ENO2—bone cancer	1.03e-05	0.000988	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—DHFR—bone cancer	1.01e-05	0.000967	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	9.64e-06	0.000923	CbGpPWpGaD
Meloxicam—PTGS2—Disease—DHFR—bone cancer	9.58e-06	0.000917	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—GNA11—bone cancer	9.44e-06	0.000904	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—ENO2—bone cancer	8.65e-06	0.000828	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—NT5C3A—bone cancer	8.62e-06	0.000825	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—CYP3A4—bone cancer	8.56e-06	0.00082	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	8.52e-06	0.000815	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—DHFR—bone cancer	8.02e-06	0.000768	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—TP53—bone cancer	7.9e-06	0.000757	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—GNA11—bone cancer	7.5e-06	0.000718	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—GSTP1—bone cancer	7.32e-06	0.000701	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—ENO2—bone cancer	7.04e-06	0.000673	CbGpPWpGaD
Meloxicam—PTGS2—Disease—TGFBR2—bone cancer	6.94e-06	0.000664	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—CYP3A4—bone cancer	6.8e-06	0.000651	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—DHFR—bone cancer	6.53e-06	0.000625	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—GNA11—bone cancer	6.1e-06	0.000584	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—GSTP1—bone cancer	5.81e-06	0.000556	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—ENO2—bone cancer	5.73e-06	0.000548	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—CYP3A4—bone cancer	5.53e-06	0.000529	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	5.5e-06	0.000527	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—DHFR—bone cancer	5.31e-06	0.000508	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—GNA11—bone cancer	4.97e-06	0.000475	CbGpPWpGaD
Meloxicam—PTGS2—Disease—KIT—bone cancer	4.74e-06	0.000453	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—GSTP1—bone cancer	4.73e-06	0.000453	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—CYP3A4—bone cancer	4.5e-06	0.000431	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	4.48e-06	0.000429	CbGpPWpGaD
Meloxicam—PTGS2—Disease—BRAF—bone cancer	4.45e-06	0.000426	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—GSTP1—bone cancer	3.85e-06	0.000368	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—PTGS2—bone cancer	3.79e-06	0.000363	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—ENO2—bone cancer	3.78e-06	0.000361	CbGpPWpGaD
Meloxicam—PTGS2—Disease—MDM2—bone cancer	3.73e-06	0.000357	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—DHFR—bone cancer	3.5e-06	0.000335	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—GNA11—bone cancer	3.27e-06	0.000313	CbGpPWpGaD
Meloxicam—PTGS2—Disease—EGFR—bone cancer	2.55e-06	0.000244	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—GSTP1—bone cancer	2.54e-06	0.000243	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—PTGS2—bone cancer	2.45e-06	0.000235	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—PTGS2—bone cancer	1.99e-06	0.000191	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—PTGS2—bone cancer	1.32e-06	0.000126	CbGpPWpGaD
